.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Healthtrust
Daiichi Sankyo
Novartis
Covington
Harvard Business School
Cipla
Fuji
Baxter

Generated: July 22, 2017

DrugPatentWatch Database Preview

Wyeth Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS INC, and what generic alternatives to WYETH PHARMS INC drugs are available?

WYETH PHARMS INC has thirty-one approved drugs.

There are eighteen US patents protecting WYETH PHARMS INC drugs on WYETH PHARMS INC drugs in the past three years.

There are three hundred and ten patent family members on WYETH PHARMS INC drugs in sixty-four countries.

Summary for Applicant: Wyeth Pharms Inc

Patents:18
Tradenames:29
Ingredients:19
NDAs:31
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 1997ABRXYesNo6,274,171*PED► SubscribeY► Subscribe
Wyeth Pharms Inc
INDERAL
propranolol hydrochloride
TABLET;ORAL016418-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
Wyeth Pharms Inc
ZOSYN IN PLASTIC CONTAINER
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050750-002Feb 24, 1998RXYesYes6,207,661► SubscribeY ► Subscribe
Wyeth Pharms Inc
LODINE XL
etodolac
TABLET, EXTENDED RELEASE;ORAL020584-001Oct 25, 1996DISCNNoNo► Subscribe► Subscribe
Wyeth Pharms Inc
ZOSYN IN PLASTIC CONTAINER
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050750-001Feb 24, 1998RXYesYes6,207,661► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc
MYLOTARG
gemtuzumab ozogamicin
INJECTABLE;INJECTION021174-001May 17, 20005,739,116► Subscribe
Wyeth Pharms Inc
EFFEXOR
venlafaxine hydrochloride
TABLET;ORAL020151-005Dec 28, 19935,916,923► Subscribe
Wyeth Pharms Inc
LODINE
etodolac
CAPSULE;ORAL018922-002Jan 31, 19914,076,831► Subscribe
Wyeth Pharms Inc
EFFEXOR
venlafaxine hydrochloride
TABLET;ORAL020151-002Dec 28, 19934,535,186*PED► Subscribe
Wyeth Pharms Inc
PREMPRO
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020527-005Jun 4, 20035,547,948► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for WYETH PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
desvenlafaxine succinate
Extended-release Tablets 25 mg
PRISTIQ
5/8/2015
desvenlafaxine succinate
Extended-release Tablets50 mg and 100 mg
PRISTIQ
2/29/2012
piperacillin sodium and tazobactam sodium
For Injection12 g/1.5 g per vial (pharmacy bulk)
ZOSYN
12/6/2011
levonorgestrel and ethinyl estradiol
Tablets0.09 mg/0.02 mg
LYBREL
10/5/2007
venlafaxine hydrochloride
Extended-release Tablets37.5 mg, 75 mg and 150 mg
EFFEXOR XR
5/3/2007
venlafaxine hydrochloride
Tablets25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg
EFFEXOR
11/3/2005
pantoprazole sodium
Delayed-release Tablets20 mg and 40 mg
PROTONIX
2/2/2004

Non-Orange Book Patents for Wyeth Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,498,312Compositions containing piperacillin and tazobactam useful for injection► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Wyeth Pharms Inc Drugs

Country Document Number Estimated Expiration
Poland212943► Subscribe
World Intellectual Property Organization (WIPO)2004091666► Subscribe
Japan4771565► Subscribe
Japan2003521470► Subscribe
Uruguay27175► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Wyeth Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
C0032Belgium► SubscribePRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Accenture
Farmers Insurance
Federal Trade Commission
Merck
Citi
QuintilesIMS
Express Scripts
US Army
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot